• Report – Going Live: Implementation of the Disclosure Code

Report – Going Live: Implementation of the Disclosure Code

  • February 4th, 2015
EFPIA’s ‘Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ has now gone live, with member companies in 33 countries starting to collect data. Representatives of practitioners, patients and the industry met at the end of January to discuss the next steps in implementation.
  • Leading Polish Physician Expresses Doubts About Financial Transparency

Leading Polish Physician Expresses Doubts About Financial Transparency

  • December 18th, 2014

By Zbigniew Gaciong


Implementing EFPIA’s code on transfers of value involves an inequitable level of disclosure by individual doctors and will leave members of the medical profession in Poland open to media sensation, says Zbigniew Gaciong, Chairman of the Department of Internal Medicine, Hypertension and Vascular Diseases at the Medical University of Warsaw
  • Ensure the Benefits of Financial Transparency are Properly Understood

Ensure the Benefits of Financial Transparency are Properly Understood

  • December 18th, 2014

By Athanasios Exadaktylos


While financial transparency will have an important long term impact, there is potential for misunderstanding of the initiative in the short term, believes Athanasios Exadaktylos, Chairman of Thessaloniki Medical Chamber. It is essential to explain the benefits, Dr Exadaktylos says in this Q&A with pharmadisclosure.eu
  • Moving to Implementation: Accurate and Complete Data Helps Patients and Defuses Hype

Moving to Implementation: Accurate and Complete Data Helps Patients and Defuses Hype

  • December 18th, 2014

by Lode Wigersma


While there is understandable concern in the medical profession that financial disclosure will fuel media sensation, the Dutch experience indicates that showing exactly how much was paid to who, for what, neutralises speculation, says Lode Wigersma, former director of the Royal Dutch Medical Association
  • Disclosure update from Ireland

Disclosure update from Ireland

  • December 12th, 2014

By Gary Finnegan

Pharmaceutical firms will publish details of "transfers of value" to health professionals as part of a new industry-wide transparency drive for the first time in 2016.
  • Making Moves to Avoid Unintended Consequences of Disclosure

Making Moves to Avoid Unintended Consequences of Disclosure

  • December 3rd, 2014

By Richard Bergström


Member companies and organisations report good headway on the technical aspects of disclosure. Now it is critical to ensure that publishing transfers of value does not deter healthcare professionals from engaging with the industry, says Richard Bergström, Director General of EFPIA
  • INFARMA Reports its Members are Poised to Begin Implementation

INFARMA Reports its Members are Poised to Begin Implementation

  • December 3rd, 2014

by Pawel Sztwiertnia


With only a few weeks to go, companies are ready to start collecting data and a wide-reaching communications campaign means physicians are now taking a pragmatic approach to disclosure of transfers of value, says Paweł Sztwiertnia, General Director of INFARMA, the Polish industry association
  • Learning the Lessons From the US on Disclosure

Learning the Lessons From the US on Disclosure

  • November 20th, 2014

By Richard Bergström

The US Open Payments database got off to a less than happy start. EFPIA will tap into this experience to inform implementation of the code on disclosure in Europe, says Richard Bergström, Director General of EFPIA
  • Transparency Message Goes Out to Healthcare Professionals Across Greece

Transparency Message Goes Out to Healthcare Professionals Across Greece

  • November 20th, 2014
Greece’s industry body, the Hellenic Association of Pharmaceutical Companies (SFEE) launched its transparency code to the key stakeholders at an event in Athens, following this up with Disclosure Code Month, a national awareness campaign to explain the objectives of the code to healthcare professionals across the country.
  • Collaboration is at the Heart of Personalised Medicine – and This Must be Underpinned by Trust

Collaboration is at the Heart of Personalised Medicine – and This Must be Underpinned by Trust

  • October 21st, 2014

by Carin Smand

Translating the basic science of genomics into medical innovation in the form of personalised medicines requires a high level of interchange between healthcare professionals and the industry. It is critical that these relationships are based on trust and a mutual understanding, says Carin Smand, Managing Director of the European Haematology Association.
  • Cloudy Outlook as Sun Rises on Open Payments

Cloudy Outlook as Sun Rises on Open Payments

  • October 21st, 2014
The US database disclosing transfers of value from pharma and medical technology companies to doctors went live at the end of September with details of 4.4 million transactions. But there are complaints it has not delivered transparency
  • Germany reports progress in implementing financial disclosure rules

Germany reports progress in implementing financial disclosure rules

  • September 19th, 2014

by Holger Diener

Over the past ten years pharmaceutical companies in Germany have proactively responded to the general trend towards greater transparency that has swept across public and corporate life. This puts the industry on the front foot in implementing the new financial disclosure code, says Dr Holger Diener, Managing Director, Association of Voluntary Self-Regulation for the Pharmaceutical Industry
  • Pharma cannot develop drugs in an office

Pharma cannot develop drugs in an office

  • September 19th, 2014

by Professor Martine Piccart

The industry simply does not have the expertise to develop the best drugs on its own. Companies must have access to clinical specialists – and the general public needs to understand the importance of this unique interaction between pharma and cancer experts, says Professor Martine Piccart, President of the European Cancer Organisation, ECCO
  • Explain the Value of the Relationship, Not the Value of the Transaction

Explain the Value of the Relationship, Not the Value of the Transaction

  • July 16th, 2014

by Michel Ballieu

The move to financial transparency must not be allowed to damage the reputation of healthcare professionals and healthcare organisations. To avoid this, the pharma industry must make the public aware of the pivotal role that its relationship with clinicians has in developing new medicines. The communications campaign should be overseen jointly by the medical profession and the industry, says Michel Ballieu, CEO of the European CanCer Organisation
  • Consultation is Vital, and the Public Needs to Understand Why This is So

Consultation is Vital, and the Public Needs to Understand Why This is So

  • July 16th, 2014

by Donald Singer

The question of whether there is a need for the pharma industry to consult clinicians and pharmacologists is not at issue. What is critical is that everyone is open about this involvement, says Professor Donald Singer, Secretary of the European Association for Clinical Pharmacology and Therapeutics
  • Nefarma Leads the Way on Transparency

Nefarma Leads the Way on Transparency

  • June 25th, 2014

by Michel A. Dutrée

As EFPIA’s members prepare to make public disclosure of payments to healthcare professionals, Michel Dutrée, Director General of Nefarma describes how the Dutch industry association has taken a lead in establishing a central register, and offers his insights on the process
  • It Will Happen, So it is Better to Get Ready Now

It Will Happen, So it is Better to Get Ready Now

  • June 25th, 2014

by Robert Schaefer

Healthcare professionals are in favour of transparency, but they have concerns about the practicalities. Not only will the onus to disclose fall to them, there is disquiet about the increasing number and variety of public disclosure platforms, the effect on doctor-patient relationships, and about the lack of public awareness and understanding of what payments are for, says Robert Schaefer
  • Financial Disclosure Supports Pharma’s Evidence-based Business Model

Financial Disclosure Supports Pharma’s Evidence-based Business Model

  • June 25th, 2014

by Stefan Gijssels

Transparency will demonstrate how the interchange between pharma and healthcare adds value and speeds the translation of research into new medicines. It will also provide the public with information to which it should have access, says Stefan Gijssels
  • This Project Talks About the Fundamentals

This Project Talks About the Fundamentals

  • June 12th, 2014

by Paweł Sztwiertnia

Financial disclosure provides a means to highlight the level of cooperation that pharma has with doctors, patients’ groups and research institutions. That may be in the industry’s interest, but it is also in the public interest, says Paweł Sztwiertnia, General Director of Infarma, the Polish industry association
  • Communicating the Objectives of Financial Disclosure  (4/4)

Communicating the Objectives of Financial Disclosure (4/4)

  • June 12th, 2014
Healthcare bodies must help in building understanding of financial disclosure, contributing to the communication strategy, communicating with the general public, and in checking their own data to make sure the system is reliable
  • Launch of Pharmadisclosure.eu – Doctors and Industry Collaborate for Better Trust

Launch of Pharmadisclosure.eu – Doctors and Industry Collaborate for Better Trust

  • May 30th, 2014
Richard Bergström, Executive Director of EFPIA launched pharmadisclosure.eu this week, committing the industry to be “absolutely transparent” about its financial relationships with healthcare professionals. Work is in hand to set up registries of payments or other forms of support. Now it is time to communicate with three million healthcare professionals in Europe, to explain how this will be put into practice.
  • Financial Transparency: the View From the ABPI

Financial Transparency: the View From the ABPI

  • May 29th, 2014

by Stephen Whitehead

The UK pharma industry has a proud heritage of discovering new medicines. It has not achieved this in isolation but in collaboration with healthcare professionals and this relationship must be preserved, says Stephen Whitehead
  • INTERVIEW: EFPIA President Christopher A. Viehbacher – Transparency, European Industry and Sanofi

INTERVIEW: EFPIA President Christopher A. Viehbacher – Transparency, European Industry and Sanofi

  • May 24th, 2014
This website has been developed as a joint initiative between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and VitalTransformation.com to highlight the industry’s new rules on disclosing financial relationships with doctors and healthcare organisations, follow progress in the implementation and to monitor compliance in the 33 countries involved in the initiative.
  • The US View on Financial Transparency

The US View on Financial Transparency

  • May 22nd, 2014
As Europe lays the ground for the voluntary, ‘Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’ pharmaceutical companies in the U.S. are working to comply with a statutory system that came into effect in August 2013.